TrialBMC cancer2024

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Andrea Necchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.